共 7 条
- [1] Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009[J] . Donald Poon,Benjamin O Anderson,Li-Tzong Chen,Koichi Tanaka,Wan Yee Lau,Eric Van Cutsem,Harjit Singh,Wan Cheng Chow,London Lucien Ooi,Pierce Chow,Maung Win Khin,Wen Hsin Koo.Lancet Oncology . 2009 (11)
- [2] Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease[J] . Paul Michael Grossman,Farrell Mendelsohn,Timothy D. Henry,James B. Hermiller,Marc Litt,Jorge F. Saucedo,Robert J. Weiss,David E. Kandzari,Neal Kleiman,R. David Anderson,Daniel Gottlieb,Ronald Karlsberg,Jeffery Snell,Krishna Rocha-Singh.American Heart Journal . 2007 (5)
- [4] Anti-apoptotic effects of the angiogenic factor Del1 on endothelial cells[J] . Z. Wang,M.T. Longaker,G.P. Yang.Journal of Surgical Research . 2006 (2)
- [6] Microvessel density of hepatocellular carcinoma: its relationship with prognosis[J] . Hui-Chuan Sun,Zhao-You Tang,Xiao-Ming Li,Yan-Nan Zhou,Bao-Rong Sun,Zeng-Chen Ma.Journal of Cancer Research and Clinical Oncology . 1999 (7)
- [7] Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma[J] . Akitaka Yamamoto,Dipok Kumar Dhar,Osama Nazmy El-Assal,Igarashi Masahiko,Tabara Hideki,Nagasue Naofumi.Journal of Hepatology . 1998 (2)